Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jean deKernion, M.D.
Jean deKernion, M.D.



General Information:



Professor and Chair, Department of Urology
Senior Associate Dean, David Geffen School of Medicine at UCLA
Physician, Department of Urology, Urologic Oncology, Prostate Cancer Program, Kidney Cancer Program, Bladder Cancer Program
Member, JCCC Patients and Survivors Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Surgical Oncology, National Cancer Institute, 1968 - 1969
Urology and General Surgery, University Hospitals of Cleveland, 1969 - 1973
Urology, University Hospitals of Cleveland, 1967 - 1968
Surgery, University Hospitals of Cleveland, 1966 - 1967
Surgery, University Hospitals of Cleveland, 1965 - 1966
Medical Degree:
M.D., Louisiana State University Medical Center, 1965


Board Certification(s):
Urology, American Board of Urology, 1975
Surgery, American Board of Surgery, 1973

Contact Information:

(310) 794-7700 Urology and Genitourinary Oncology information and referral
(310) 206-6909 Genitourinary Oncology referring physician
(310) 206-5930 Kidney Cancer Program information and referral
(310) 451-8751 Kidney Cancer Program referring physician
(310) 794-7704 or (310) 206-0297 Prostate Research and Treatment Program information and referral
(310) 794-7700 Prostate Research and Treatment Program referring physician

Practice Information:

Clinical Interest(s):
Bladder Cancer
Congenital Adult
Congenital Pediatrics
Kidney Cancer
Nerve Sparing Prostatectomy
Penile Cancer
Prostate Cancer
Prostate Nodules
Testicular Cancer
Testicular Mass-Pain
Ureteral Obstruction
Urinary Diversion

Scientific Interest(s):

Dr. Jean deKernion is interested in clinical and basic research in genitourinary malignancies, especially prostate cancer.

Selected Cancer-Related Publications:

deKernion JB. Society of Urologic Oncology: Whitmore lecture. Urol Oncol. 2006; 24(4): 318-21.

deKernion JB. Reexamination of current staging for renal cell carcinoma. J Urol. 2005; 173(3): 680.

Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005; 114(2): 268-73.

Mao GE, Reuter VE, Cordon-Cardo C, Dalbagni G, Scher HI, DeKernion JB, Zhang ZF, Rao J. Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. Cancer Epidemiol Biomarkers Prev. 2004; 13(3): 383-90.

Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003; 169(3): 909-16.